team header new
mobile header 3


Replimune is developing the next generation of oncolytic immunotherapies using a proprietary new high potency backbone virus which is engineered for oncolytic use (RP1). RP1 is itself expected to be a very potent activator of both innate and adaptive immune responses. RP1 is then used to deliver certain optimized immune activating proteins directly into the immune response-initiating tumor and to draining lymph nodes. This is expected to focus immune activation and potentiation on tumor antigens and reduce the toxicity often seen with systemic antibody based approaches.

pipeline slide final